Table of Content

Introduction
Executive Summary
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview
? Causes
? Mechanism of Action
? Signs and Symptoms
? Diagnosis
? Disease Management
Pipeline Therapeutics
? Comparative Analysis
Therapeutic Assessment
? Assessment by Product Type
? Assessment by Stage and Product Type
? Assessment by Route of Administration
? Assessment by Stage and Route of Administration
? Assessment by Molecule Type
? Assessment by Stage and Molecule Type
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
? Transthyretin Amyloid Cardiomyopathy (ATTR-CM) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Collaboration Deals
? Company-Company Collaborations (Licensing / Partnering) Analysis
? Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
? Comparative Analysis
Acoramidis: Eidos Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase I)
? Comparative Analysis
NI006: NeuraImmune Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Pre-clinical and Discovery Stage Products
? Comparative Analysis
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
? Comparative Analysis
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Companies
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Products
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- Unmet Needs
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- Market Drivers and Barriers
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- Future Perspectives and Conclusion
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Analyst Views
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Companies
Appendix



List of Figures


Figure 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products